Mode
Text Size
Log in / Sign up
Phase 1 N=66 Treatment

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Enrolled (actual)
66
Serious AEs
31.8%
Results posted
May 2025
Primary outcome: Primary: Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 6; 10; 11; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Zanubrutinib (Drug); Lenalidomide (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
BeiGene
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
6; 10; 11; 0; 3; 4
PRIMARY
Part 2: Overall Response Rate (ORR)
48.7; 58.0
SECONDARY
Part 1: Overall Response Rate (ORR)
16.7; 30.0; 90.9
SECONDARY
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Zanubrutinib After a Single Dose and at Steady State
847.8; 623.9
SECONDARY
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Zanubrutinib After a Single Dose and at Steady State
798.4; 638.4
SECONDARY
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Zanubrutinib After a Single Dose
943.3
SECONDARY
Maximum Plasma Concentration (Cmax) of Zanubrutinib After a Single Dose and at Steady State
281.2; 208.7
SECONDARY
Time to Maximum Plasma Concentration (Tmax) of Zanubrutinib After a Single Dose and at Steady State
2.0; 2.5
SECONDARY
Time to the Last Quantifiable Concentration (Tlast) of Zanubrutinib After a Single Dose and at Steady State
7.9; 7.9
SECONDARY
Apparent Terminal Elimination Half-life (T1/2) of Zanubrutinib After a Single Dose and at Steady State
1.4; 1.6
SECONDARY
Apparent Volume (CL/F) of Zanubrutinib After a Single Dose and at Steady State
165.9; 226.5
SECONDARY
Apparent Clearance (Vz/F) of Zanubrutinib After a Single Dose and at Steady State
341.4; 533.8
SECONDARY
Accumulation Ratio of AUCt for Zanubrutinib
0.7
SECONDARY
Accumulation Ratio of Cmax for Zanubrutinib
0.8
SECONDARY
Area Under the Plasma Concentration-time Curve From Zero to 8 Hours Postdose (AUCt) of Lenalidomide After a Single Dose and at Steady State
843.5; 1092.5; 1177.7; 1091.0; 916.1; 1702.6
SECONDARY
AUClast of Lenalidomide After a Single Dose and at Steady State
641.9; 1072.7; 1187.4; 778.7; 824.6; 1389.7
SECONDARY
AUCinf of Lenalidomide After a Single Dose
933.7; 1443.2; 1752.4
SECONDARY
Cmax of Lenalidomide After a Single Dose and at Steady State
206.4; 276.5; 332.0; 238.5; 206.6; 372.1
SECONDARY
Tmax of Lenalidomide After a Single Dose and at Steady State
1.5; 1.5; 2.0; 1.9; 2.1; 1.9
SECONDARY
Tlast of Lenalidomide After a Single Dose and at Steady State
7.6; 7.9; 8.0; 7.7; 7.7; 8.0
SECONDARY
T1/2 of Lenalidomide After a Single Dose and at Steady State
2.3; 2.7; 2.5; 2.0; 2.3; 2.4
SECONDARY
CL/F of Lenalidomide After a Single Dose and at Steady State
16.1; 16.0; 13.9; 12.8; 17.6; 12.5
SECONDARY
Vz/F of Lenalidomide After a Single Dose and at Steady State
53.6; 62.1; 49.7; 37.3; 57.6; 43.6
SECONDARY
Accumulation Ratio of AUCt for Lenalidomide
1.1; 0.8; 1.0
SECONDARY
Accumulation Ratio of Cmax for Lenalidomide
1.3; 0.8; 0.9
SECONDARY
Part 1: Overall Response Rate by Immunohistochemistry Subtypes
33.3; 0.0; 50.0; 16.7; 66.7; 100.0
SECONDARY
Part 1: Overall Response Rate by Gene Expression Profiling (GEP) Subtypes
0.0; 0.0; 12.5; 100.0; 88.9; 100.0
SECONDARY
Part 2: Overall Response Rate by Immunohistochemistry Subtypes
50.0; 61.8
SECONDARY
Part 2: Overall Response Rate by Gene Expression Profiling Subtypes
68.6; 45.5
SECONDARY
Part 2: Complete Response Rate (CRR)
33.3; 42.0
SECONDARY
Part 2: Complete Response Rate by Immunohistochemistry Subtypes
50.0; 38.2
SECONDARY
Part 2: Complete Response Rate by Gene Expression Profiling Subtypes
45.7; 45.5
SECONDARY
Part 2: Duration of Response (DOR)
9.10; 14.92
SECONDARY
Part 2: Duration of Response by Immunohistochemistry Subtypes
NA; 11.61
SECONDARY
Part 2: Duration of Response by Gene Expression Profiling Subtypes
15.67; 9.10
SECONDARY
Part 2: Progression-free Survival (PFS)
4.76; 5.52
SECONDARY
Part 2: Progression-Free Survival by Immunohistochemistry Subtypes
5.55; 5.52
SECONDARY
Part 2: Progression-Free Survival by Gene Expression Profiling Subtypes
5.55; 5.40
SECONDARY
Part 2: Time to Response (TTR)
2.76; 2.76
SECONDARY
Part 2: Time to Response by Immunohistochemistry Subtypes
2.87; 2.76
SECONDARY
Part 2: Time to Response by Gene Expression Profiling Subtypes
2.76; 3.19
SECONDARY
Part 2: Number of Participants With Treatment-emergent Adverse Events
39; 14

Summary

The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL

Eligibility Criteria

Key Inclusion Criteria

  • Histologically confirmed DLBCL, all participants must provide sufficient archival or fresh tumor tissue samples for evaluation by immunohistochemistry (IHC) and Gene Expression Profiling (GEP).
  • Relapsed or refractory disease, defined as either: 1) progression of disease after having achieved disease remission (complete response [CR] or partial response [PR]) , or 2) stable disease (SD), or progressive disease (PD) at completion of the treatment regimen preceding entry to the study.
  • Participants who have not received high dose therapy/stem cell transplantation (HDT/SCT) must be ineligible for HDT/SCT.
  • Measurable disease as defined by at least 1 lymph node >1.5 cm in longest diameter, or at least 1 extra-nodal lesion >1.0 cm in longest diameter, and measurable in 2 perpendicular dimensions.
  • Received an appropriate first-line therapy for DLBCL,defined as an anti CD20 antibody and an appropriate anthracycline-based combination therapy for at least 2 cycles, unless the patient is intolerant or had disease progression before Cycle 2..

Key Exclusion Criteria

  • Current or history of central nervous system (CNS) lymphoma.
  • Histologically transformed lymphoma.
  • History of allogeneic stem-cell transplantation.
  • Prior exposure to a BTK inhibitor.
  • Prior exposure to lenalidomide or thalidomide.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04436107). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search